Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01672775 (Clinical Trial/ AGS-16C3F/ AGS-16M8F/ AGS 16C3F)

Study Title
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology (NCT01672775)

Trial Description
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F (also known as AGS-16M8F/ AGS 16C3F)  in subjects with renal cell cancer (RCC). This trial is sponsored by Agensys/Astellas Pharma. [1]

Study Data

  • Condition: Renal Cell Carcinoma
  • Interventions:
    • Drugs used in this trial
      • AGS-16C3F (AGS-16M8F/ AGS 16C3F)
  • Phase: I
  • Enrollment: 34
  • Start: July 2012
  • Estimated Completion: September 2015
  • Last verified: March 2015

Study Schematic

NCT01672775

Click here to Return to Drug map


Last Editorial review: August 28, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar